Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 30, 2020

Sanofi begins dosing of DNL758 in Phase Ib Covid-19 trial

Denali Therapeutics has announced that its partner Sanofi has started dosing of a small molecule RIPK1 inhibitor, DNL758, in a Phase Ib clinical trial involving hospitalised adults with severe Covid-19 lung disease.

Denali Therapeutics has announced that its partner Sanofi has started dosing of a small molecule RIPK1 inhibitor, DNL758, in a Phase Ib clinical trial involving hospitalised adults with severe Covid-19 lung disease.

RIPK1, a receptor-interacting serine/threonine-protein kinase 1, serves as a signaling protein in the TNF receptor pathway, which modulates inflammation and cell death in body tissues.

In severe Covid-19 patients, a RIPK1 inhibitor is expected to reduce the exaggerated immune response to SARS-CoV-2 and limit any tissue damage caused by excessive inflammation.

The randomised, double-blind, placebo-controlled Phase Ib study is designed to assess DNL758’s safety and impact on the immune system in severe Covid-19 cases.

The study will be completed in January next year and is expected to enrol around 67 participants.

Denali Therapeutics CEO Ryan Watts said: “We know that inhibition of RIPK1, a known target in the TNF-pathway, can significantly modulate the body’s immune response.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“Our partner Sanofi is expanding its clinical investigation of DNL758 into patients with severe Covid-19. We are proud to stand with Sanofi in this effort, with the aim to contribute solutions in the fight against this terrible pandemic.”

Denali and Sanofi collaborated in October 2018 for the global development and commercialisation of RIPK1 inhibitors.

Apart from Covid-19, the company are evaluating DNL788 in CNS indications and DNL758 in peripheral inflammatory indications.

Sanofi agreed to develop and commercialise DNL758, as well as cover all costs related to the drug candidate, while Denali is eligible for development and sales milestones and sales royalties.

Earlier this month, Sanofi and Regeneron Pharmaceuticals reported that a Phase III trial of rheumatoid arthritis drug Kevzara failed to meet its primary and key secondary endpoints in Covid-19 patients who required mechanical ventilation in the US.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU